Abstract
The Cancer Stem Cells (CSCs) theory suggests that genetic alterations in stem cells are the direct cause for cancer. The evidence for a CSC population that results in pituitary tumors is poor. Some studies report the isolation of CSCs, but a deep characterization of the stemness of these cells is lacking. Here, we report the isolation and detailed characterization of progenitor mesenchymal cells (PMCs) from both growth hormone-secreting (GH+) and non-secreting (NS) pituitary adenomas, determining the immunophenotype, the expression of genes related to stemness or to pituitary hormone cell types, and the differentiative potential towards osteo-, chondro- and adipogenic lineages. Finally, the expression of CD133, known as a marker for CSCs in other tumors, was analyzed. Isolated cells, both from GH+ and NS tumors, satisfy all the criteria for the identification of PMCs and express known stem cell markers (OCT4, SOX2, KLF4, NANOG), but do not express markers of pituitary hormone cell types (PITX2, PROP1, PIT1). Finally, PMCs express CD133. We demonstrated that pituitary tumors contain a stem cell population that can generate cell types characteristic of mesenchymal stem cells, and express CD133, which is associated with CSCs in other tumors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE . The prevalence of pituitary adenomas: a systematic review. Cancer 2004; 101: 613–619.
Melmed S . Pathogenesis of pituitary tumors. Nat Rev Endocrinol 2011; 7: 257–266.
Bonnet D, Dick JE . Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730–737.
Wang JC . Good cells gone bad: the cellular origins of cancer. Trends Mol Med 2010; 16: 145–151.
Wang ML, Chiou SH, Wu CW . Targeting cancer stem cells: emerging role of Nanog transcription factor. Onco Targets Ther 2013; 6: 1207–1220.
Xu Q, Yuan X, Tunici P, Liu G, Fan X, Xu M et al. Isolation of tumour stem-like cells from benign tumours. Br J Cancer 2009; 101: 303–311.
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315–317.
Irollo E, Pirozzi G . CD133: to be or not to be, is this the real question? Am J Transl Res 2013; 5: 563–581.
Orciani M, Gorbi S, Benedetti M, Di Benedetto G, Mattioli-Belmonte M, Regoli F et al. Oxidative stress defense in human-skin-derived mesenchymal stem cells versus human keratinocytes: Different mechanisms of protection and cell selection. Free Radic Biol Med 2010; 49: 830–838.
Orciani M, Campanati A, Salvolini E, Lucarini G, Di Benedetto G, Offidani A et al. The mesenchymal stem cell profile in psoriasis. Br J Dermatol 2011; 165: 585–592.
Orciani M, Di Primio R . Skin-derived mesenchymal stem cells: isolation, culture, and characterization. Methods Mol Biol 2013; 989: 275–283.
Salvolini E, Lucarini G, Zizzi A, Orciani M, Di Benedetto G, Di Primio R . Human skin-derived mesenchymal stem cells as a source of VEGF and nitric oxide. Arch Dermatol Res 2010; 302: 367–374.
Halfon S, Abramov N, Grinblat B, Ginis I . Markers distinguishing mesenchymal stem cells from fibroblasts are downregulated with passaging. Stem Cells Dev 2011; 20: 53–66.
Kim MJ, Shin KS, Jeon JH, Lee DR, Shim SH, Kim JK et al. Human chorionic-plate-derived mesenchymal stem cells and Wharton's jelly-derived mesenchymal stem cells: a comparative analysis of their potential as placenta-derived stem cells. Cell Tissue Res 2011; 346: 53–64.
Orciani M, Emanuelli M, Martino C, Pugnaloni A, Tranquilli AL, Di Primio R . Potential role of culture mediums for successful isolation and neuronal differentiation of amniotic fluid stem cells. Int J Immunopathol Pharmacol 2008; 21: 595–602.
Orciani M, Morabito C, Emanuelli M, Guarnieri S, Sartini D, Giannubilo SR et al. Neurogenic potential of mesenchymal-like stem cells from human amniotic fluid: the influence of extracellular growth factors. J Biol Regul Homeost Agents 2011; 25: 115–130.
Salvolini E, Orciani M, Lucarini G, Vignini A, Tranquilli AL, Di Primio R . VEGF and nitric oxide synthase immunoexpression in Down's syndrome amniotic fluid stem cells. Eur J Clin Invest 2011; 41: 23–29.
Lazzarini R, Olivieri F, Ferretti C, Mattioli-Belmonte M, Di Primio R, Orciani M . mRNAs and miRNAs profiling of mesenchymal stem cells derived from amniotic fluid and skin: the double face of the coin. Cell Tissue Res 2014; 355: 121–130.
Castinetti F, Davis SW, Brue T, Camper SA . Pituitary stem cell update and potential implications for treating hypopituitarism. Endocr Rev 2010; 32: 453–471.
de Moraes DC, Vaisman M, Conceição FL, Ortiga-Carvalho TM . Pituitary development: a complex, temporal regulated process dependent on specific transcriptional factors. J Endocrinol 2012; 215: 239–245.
Ward RD, Raetzman LT, Suh H, Stone BM, Nasonkin IO, Camper SA . Role of PROP1 in pituitary gland growth. Mol Endocrinol 2005; 19: 698–710.
Zhu X, Gleiberman AS, Rosenfeld MG . Molecular physiology of pituitary development: signaling and transcriptional networks. Physiol Rev 2007; 87: 933–963.
Bao B, Ahmad A, Li Y, Azmi AS, Ali S, Banerjee S, Kong D et al. Targeting CSCs within the tumor microenvironment for cancer therapy: a potential role of mesenchymal stem cells. Expert Opin Ther Targets 2012; 16: 1041–1054.
Jamal M, Rath BH, Tsang PS, Camphausen K, Tofilon PJ . The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells. Neoplasia 2012; 14: 150–158.
Yunoue S, Arita K, Kawano H, Uchida H, Tokimura H, Hirano H . Identification of CD133+ cells in pituitary adenomas. Neuroendocrinology 2011; 94: 302–312.
Nassiri F, Cusimano M, Zuccato JA, Mohammed S, Rotondo F, Horvath E et al. Pituitary stem cells: candidates and implications. Pituitary 2013; 16: 413–418.
Lloyd RV, Hardin H, Montemayor-Garcia C, Rotondo F, Syro LV, Horvath E et al. Stem cells and cancer stem-like cells in endocrine tissues. Endocr Pathol 2013; 24: 1–10.
De Coppi P, Bartsch G Jr, Siddiqui MM, Xu T, Santos CC, Perin L, Mostoslavsky G et al. Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol 2007; 25: 100–106.
Couly G, Coltey P, Eichmann A, Le Douarin NM . The angiogenic potentials of the cephalic mesoderm and the origin of brain and head blood vessels. Mech Dev 1995; 53: 97–112.
Etchevers HC, Vincent C, Le Douarin NM, Couly GF . The cephalic neural crest provides pericytes and smooth muscle cells to all blood vessels of the face and forebrain. Development 2001; 128: 1059–1068.
Yamanishi E, Takahashi M, Saga Y, Osumi N . Penetration and differentiation of cephalic neural crest-derived cells in the developing mouse telencephalon. Dev Growth Differ 2012; 54: 785–800.
Phinney DG . Functional heterogeneity of mesenchymal stem cells: implications for cell therapy. J Cell Biochem 2012; 113: 2806–2812.
Le H, Zeng F, Xu L, Liu X, Huang Y . The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer. Mol Med Rep 2013; 8: 1511–1518.
Ren F, Sheng WQ, Du X . CD133: a cancer stem cells marker, is used in colorectal cancers. World J Gastroenterol 2013; 19: 2603–2611.
Yang K, Chen XZ, Zhang B, Yang C, Chen HN, Chen ZX et al. Is CD133 a biomarker for cancer stem cells of colorectal cancer and brain tumors? A meta-analysis. Int J Biol Markers 2011; 26: 173–180.
Östman A . Cancer-associated fibroblasts: recent developments and emerging challenges. Semin Cancer Biol 2014; 25: 1–2.
Acknowledgements
This work was supported by grant FIRB-RBAP10MLK7_003 and FIRB-RBAP1153LS_004 from Ministero dell’Istruzione, dell’Università e della Ricerca, Rome, Italy.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Orciani, M., Davis, S., Appolloni, G. et al. Isolation and characterization of progenitor mesenchymal cells in human pituitary tumors. Cancer Gene Ther 22, 9–16 (2015). https://doi.org/10.1038/cgt.2014.63
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cgt.2014.63
This article is cited by
-
Identification and gene expression profiling of human gonadotrophic pituitary adenoma stem cells
Acta Neuropathologica Communications (2023)
-
Up-regulation of sex-determining region Y-box 9 (SOX9) in growth hormone-secreting pituitary adenomas
BMC Endocrine Disorders (2021)
-
Pituitary adenomas, stem cells, and cancer stem cells: what’s new?
Journal of Endocrinological Investigation (2018)
-
Effects of somatostatin and its analogues on progenitor mesenchymal cells isolated from human pituitary adenomas
Pituitary (2017)
-
Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas
Molecular Neurobiology (2017)